The estimated Net Worth of Venture Investments, Llc Al... is at least 7.67 百万$ dollars as of 18 September 2020. Venture Al owns over 38,461 units of Silverback Therapeutics stock worth over 7,673,593$ and over the last 7 years Venture sold SBTX stock worth over 0$.
Sign up
Venture Al SBTX stock SEC Form 4 insiders trading
Venture has made over 5 trades of the Silverback Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Venture bought 38,461 units of SBTX stock worth 499,993$ on 18 September 2020.
The largest trade Venture's ever made was buying 136,364 units of Silverback Therapeutics stock on 30 July 2018 worth over 1,500,004$. On average, Venture trades about 22,964 units every 56 days since 2017. As of 18 September 2020 Venture still owns at least 1,307,256 units of Silverback Therapeutics stock.
You can see the complete history of Venture Al stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Venture Al's mailing address?
Venture's mailing address filed with the SEC is 385 E Colorado Blvd #299, Pasadena, CA 91101, USA.
Insiders trading at Silverback Therapeutics
Over the last 6 years, insiders at Silverback Therapeutics have traded over 0$ worth of Silverback Therapeutics stock and bought 2,785,936 units worth 58,491,063$ . The most active insiders traders include Peter A. Thompson、Thilo Schroeder、Advisors Llc Orbi Med Capit.... On average, Silverback Therapeutics executives and independent directors trade stock every 60 days with the average trade being worth of 1,681,567$. The most recent stock trade was executed by Laura Shawver on 5 August 2022, trading 78,740 units of SBTX stock currently worth 100,000$.
What does Silverback Therapeutics do?
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
What does Silverback Therapeutics's logo look like?
Complete history of Venture Al stock trades at Evelo Biosciences Inc、Constellation Pharmaceuticals Inc、Liquidia Corp、Nextcure Inc、Karuna Therapeutics Inc、Frequency Therapeutics Inc、Imara Inc、IDEAYA Biosciences、Avidity Biosciences、Relay Therapeutics、Kymera Therapeutics、Metacrine、Silverback Therapeutics
Silverback Therapeutics executives and stock owners
Silverback Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Laura K. Shawver,
CEO & Director -
Dr. Valerie Odegard Ph.D.,
Pres & Chief Scientific Officer -
Jonathan Piazza,
Chief Financial Officer -
Douglas Quinn,
Chief Financial Officer, Executive Director, Company Secretary -
Stuart Ashman,
Chief Executive Officer, Executive Director -
Dr. Peter A. Thompson M.D.,
Co-Founder & Chairman of Directors -
Catherine Prescott,
Non-Executive Independent Director -
Martin Hunt,
Non-Executive Independent Chairman of the Board -
Miguel Arcinas M.B.A.,
Exec. Director of Corp. Dev & IR -
Dario Gobunquin CPA,
Sr. Director of Accounting & Controller -
Sateesh Natarajan,
Sr. VP of CMC Devel. -
Scott Moorefield Ph.D.,
Sr. VP of Bus. Devel. -
Russ Hawkinson,
Sr. VP of Fin. -
Dr. Naomi Hunder M.D.,
Chief Medical Officer -
Katie Carrigan,
VP of HR -
Jeffrey C. Pepe J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Management Group Xii, L.L.C...,
-
Thilo Schroeder,
Director -
Maria Koehler,
Director -
Jonathan Piazza,
Chief Financial Officer -
Saqib Islam,
Director -
Russ Hawkinson,
Sr. Vice President of Finance -
Naomi Hunder,
Chief Medical Officer -
Valerie Odegard,
President and CSO -
Vickie L Capps,
Director -
Venture Investments, Llc Al...,
10% owner -
Robert Hershberg,
Director -
Laura Shawver,
Chief Executive Officer -
Peter A. Thompson,
Director -
Jonathan D Root,
Director -
Advisors Llc Orbi Med Capit...,